CHARLES SCHWAB INVESTMENT MANAGEMENT INC - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$8,858,440
+18.5%
1,157,966
+15.7%
0.00%
+50.0%
Q2 2023$7,475,804
+13.9%
1,000,777
+1.7%
0.00%0.0%
Q1 2023$6,562,873
-13.6%
983,939
-0.1%
0.00%0.0%
Q4 2022$7,591,891
-21.1%
984,681
+8.9%
0.00%
-33.3%
Q3 2022$9,624,000
+176.0%
904,504
+111.2%
0.00%
+200.0%
Q2 2022$3,487,000
+30.5%
428,342
+14.8%
0.00%0.0%
Q1 2022$2,672,000
-58.7%
373,164
-1.1%
0.00%
-50.0%
Q4 2021$6,463,000
+53.7%
377,239
+106.4%
0.00%
+100.0%
Q3 2021$4,206,000
-30.1%
182,772
+10.9%
0.00%
-50.0%
Q2 2021$6,019,000164,8810.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Data Collective IV GP, LLC 5,941,120$45,806,03548.11%
Kinnevik AB (publ) 7,653,061$59,005,10033.28%
MV Management XI, L.L.C. 1,971,908$15,203,41126.45%
MIC Capital Management UK LLP 8,451,758$65,163,05712.86%
ArchPoint Investors 1,114,626$8,593,7664.07%
HARVARD MANAGEMENT CO INC 1,509,254$11,636,3481.44%
PLATINUM INVESTMENT MANAGEMENT LTD 2,710,339$20,896,7140.80%
Duquesne Family Office 1,385,950$10,685,6750.53%
ALLEN OPERATIONS LLC 217,657$1,678,1350.45%
Artal Group S.A. 960,204$7,4030.41%
View complete list of RECURSION PHARMACEUTICALS IN shareholders